Invuity (NASDAQ:IVTY)‘s stock had its “buy” rating reissued by investment analysts at Northland Securities in a note issued to investors on Wednesday. They presently have a $6.00 price target on the medical instruments supplier’s stock. Northland Securities’ price objective indicates a potential upside of 51.90% from the stock’s current price.

The analysts wrote, “We would be remiss in not expressing our disappointment, and are lowering our PT to $6.””

A number of other brokerages also recently commented on IVTY. Zacks Investment Research upgraded Invuity from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a research report on Saturday, January 27th. Piper Jaffray Companies reiterated a “buy” rating and set a $12.00 price objective on shares of Invuity in a research report on Friday, November 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $8.50.

Shares of Invuity (NASDAQ:IVTY) traded down $0.55 during trading hours on Wednesday, hitting $3.95. The stock had a trading volume of 479,800 shares, compared to its average volume of 284,755. The company has a debt-to-equity ratio of 5.39, a current ratio of 2.90 and a quick ratio of 2.47. The firm has a market capitalization of $77.13, a price-to-earnings ratio of -1.60 and a beta of -0.50. Invuity has a 12-month low of $3.75 and a 12-month high of $9.70.

A number of institutional investors have recently made changes to their positions in the stock. BlueCrest Capital Management Ltd purchased a new position in Invuity during the fourth quarter worth approximately $139,000. Eversept Partners LLC purchased a new position in Invuity during the fourth quarter worth approximately $279,000. Wells Fargo & Company MN raised its position in Invuity by 987.0% in the fourth quarter. Wells Fargo & Company MN now owns 64,198 shares of the medical instruments supplier’s stock valued at $398,000 after purchasing an additional 58,292 shares during the period. Lyon Street Capital LLC raised its position in Invuity by 15.5% in the third quarter. Lyon Street Capital LLC now owns 883,355 shares of the medical instruments supplier’s stock valued at $7,862,000 after purchasing an additional 118,825 shares during the period. Finally, Discovery Group I LLC raised its position in Invuity by 9,587.9% in the third quarter. Discovery Group I LLC now owns 1,258,849 shares of the medical instruments supplier’s stock valued at $11,204,000 after purchasing an additional 1,245,855 shares during the period. Hedge funds and other institutional investors own 67.57% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Invuity’s (IVTY) Buy Rating Reaffirmed at Northland Securities” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2018/02/14/invuitys-ivty-buy-rating-reaffirmed-at-northland-securities.html.

About Invuity

Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.

Receive News & Ratings for Invuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity and related companies with MarketBeat.com's FREE daily email newsletter.